ICER's mission is to lead innovation in comparative effectiveness research through methods that integrate considerations of clinical benefit and economic value. Through a unique collaboration with patients, clinicians, manufacturers, insurers and other healthcare stakeholders, ICER develops tools to support patient decisions and medical policy that share the goal of achieving maximum value for every healthcare dollar.
|Anti-VEGF Treatment Options for Diabetic Macular Edema|
ICER completed a robust technology assessment of the treatment options for diabetic macular edema (DME) for the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting on March 21, 2012. MEDCAC is reviewing the evidence on anti-vascular endothelial growth factor (anti-VEGF) treatment options for DME, a condition marked by progressive sight loss common in patients with diabetes. The technology assessment examined the evidence on Avastin, Eylea, Lucentis and Macugen.
ICER used its expertise in comparative effectiveness research to conduct a systematic review of the evidence on the clinical effectiveness and potential harms of intravitreal agents which inhibit VEGF in patients with DME.
MEDCAC provides independent guidance and expert advice to the Centers for Medicare and Medicaid Services (CMS) on specific clinical topics and provides judgments on the strength of the available evidence. MEDCAC then makes recommendations to CMS based on that evidence to help guide coverage policy. More on this meeting is available at the CMS website.